DEPARTMENT OF HEALTH SERVICES

Division of Health Care Access and Accountability F-01674 (01/2016)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH

PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR HIDRADENITIS SUPPURATIVA

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Hidradenitis Suppurativa Completion Instructions, F-01674A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Hidradenitis Suppurativa form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I — MEMBER INFORMATION							
Name — Member (Last, First, Middle Initial)							
2. Member Identification Number	3. Date of Birth — Member						
SECTION II — PRESCRIPTION INFORMATION							
4. Drug Name	5. Drug Strength						
6. Date Prescription Written	7. Directions for Use						
o. Date i rescription written	7. Directions for ose						
8. Name — Prescriber	9. National Provider Identifier (NPI) — Prescriber		scriber				
10. Address — Prescriber (Street, City, State, ZIP+4 Code)							
11. Telephone Number — Prescriber							
SECTION III — CLINICAL INFORMATION FOR HIDRADENITIS SUPPURATIVA							
12. Diagnosis Code and Description							
13. Does the member have a diagnosis of hidradenitis suppurativa?				Yes		No	
14. Is the prescription written by a dermatologist or through a dermatology consultation?				Yes		No	
15. Does the member have recurrent abscesses with sinus tracts and scarring?				Yes		No	
16. Has the member had laser therapy, excision, or deroofing surgery to treat hidradenitis suppurativa?				Yes		No	
17. Has the member received one or more of the drug therapies listed below and received each							
treatment for at least three consecutive months and experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse reaction?				No			
_ 100 <u>_</u> 100							
If yes, check the box next to the drug therapy the member received. Indicate the drug(s) taken, dose(s), approximate date(s) the drug(s) was taken, and specific details about the unsatisfactory therapeutic response(s) or clinically significant adverse reaction(s) in the space provided.							
1. Antibiotics							
2. Retinoids							
3.							

Continued



F-01674 (01/2016)

SECTION IV — AUTHORIZED SIGNATURE						
18. SIGNATURE — Prescriber		19. Date Signed				
SECTION V — FOR PHARMACY PROVIDERS USING STAT-PA						
20. National Drug Code (11 Digits)	21. Days' Supp	21. Days' Supply Requested (Up to 365 Days)				
22. NPI						
23. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days						
in the past.)						
24. Place of Service						
25. Assigned PA Number						
26. Grant Date	27. Expiration Date	28. Number of Days Approved				
SECTION VI — ADDITIONAL INFORMATION						

29. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the product requested may be included here.